Wanbury Limited Stock Price Today (NSE: WANBURY)
Fundamental Score
Wanbury Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Wanbury Limited share price today is ₹222.60, down 0.22% on NSE/BSE as of 16 September 2026. Wanbury Limited (WANBURY) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹777.75 (Cr). The 52-week high for WANBURY share price is ₹358.85 and the 52-week low is ₹161.50. At a P/E ratio of 12.82x, WANBURY is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 64.93% and a debt-to-equity ratio of 1.49.
Wanbury Limited Share Price Chart — NSE/BSE Historical Performance
Wanbury Limited share price chart: -0.57% return over the past month. 52-week high ₹358.85, 52-week low ₹161.50.
Wanbury Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹223.85 | ₹229.30 | ₹219.00 | ₹222.60 | 1.61L (Cr) | |
| ₹237.10 | ₹240.50 | ₹220.35 | ₹223.10 | 2.27L (Cr) | |
| ₹240.00 | ₹240.40 | ₹234.75 | ₹239.35 | 59.57K (Cr) | |
| ₹244.35 | ₹249.70 | ₹240.40 | ₹241.45 | 60.10K (Cr) | |
| ₹245.10 | ₹249.75 | ₹243.10 | ₹244.75 | 60.14K (Cr) | |
| ₹250.80 | ₹256.70 | ₹246.60 | ₹247.70 | 1.04L (Cr) | |
| ₹243.10 | ₹253.00 | ₹240.00 | ₹250.55 | 1.40L (Cr) | |
| ₹243.95 | ₹249.30 | ₹243.00 | ₹246.20 | 51.91K (Cr) | |
| ₹248.40 | ₹249.50 | ₹241.00 | ₹243.35 | 91.20K (Cr) | |
| ₹254.00 | ₹254.00 | ₹243.15 | ₹245.00 | 1.16L (Cr) |
Wanbury Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹252.70 | ₹256.70 | ₹219.00 | ₹222.60 | -11.91% | |
| ₹294.00 | ₹300.95 | ₹230.00 | ₹254.10 | -13.57% | |
| ₹280.85 | ₹358.85 | ₹269.00 | ₹293.55 | +4.52% | |
| ₹286.00 | ₹297.95 | ₹248.70 | ₹280.85 | -1.80% | |
| ₹253.95 | ₹315.20 | ₹244.15 | ₹308.65 | +21.54% | |
| ₹232.87 | ₹277.65 | ₹220.50 | ₹254.28 | +9.19% | |
| ₹252.40 | ₹265.35 | ₹217.95 | ₹221.95 | -12.06% | |
| ₹205.30 | ₹284.00 | ₹203.61 | ₹265.61 | +29.38% | |
| ₹225.25 | ₹238.00 | ₹161.50 | ₹208.75 | -7.33% | |
| ₹258.20 | ₹263.90 | ₹225.00 | ₹226.60 | -12.24% | |
| ₹260.05 | ₹274.20 | ₹222.75 | ₹260.25 | +0.08% | |
| ₹257.05 | ₹270.00 | ₹222.00 | ₹262.85 | +2.26% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Wanbury Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Wanbury Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of WANBURY across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Return on Equity (64.93%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (32.30%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 12.82 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (24.14%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Excellent EPS Growth (41.19% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (47.76% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Risk Factors
6 factors identified
High Price-to-Book Ratio (12.31x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Elevated Debt Levels (D/E: 1.49)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Negative Free Cash Flow (₹-25.18 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.59%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (62.18%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Wanbury Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Wanbury Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Wanbury LimitedWanbury Limited...Selected✓ WANBURY • 524212 | 33.8/100 | ₹222.60₹223 | ₹777.75₹777.75 | 12.82Average 12.8 Average | 64.93%Excellent 64.93% Excellent | 32.30%Excellent 32.30% Excellent | 1.49Average 1.5 Average | 47.76%Excellent 47.76% Excellent | 10.62%Good 10.62% Good | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Wanbury Limited PE Ratio History
Historical price-to-earnings ratio for WANBURY — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.98 | ₹226.60 | 25.2x |
| FY 2024 | ₹16.89 | ₹291.18 | 17.2x |
| FY 2022 | ₹25.21 | ₹49.00 | 1.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Wanbury Limited Quarterly Performance
Latest quarterly metrics for WANBURY — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
1.47%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
24.14%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.62%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
47.76%
Compounded annual net profit growth over 5 years
Wanbury Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for WANBURY — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Wanbury Limited Financial Statements
Annual income statement, balance sheet and cash flow for Wanbury Limited (WANBURY) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Wanbury Limited
About WANBURY (Wanbury Limited)
Wanbury Ltd is a pharmaceutical company driven by innovation and a commitment to improving healthcare outcomes across the globe. The company formulates, develops, manufactures, and... markets a diverse portfolio of pharmaceutical products including formulations and active pharmaceutical ingredients (APIs). Wanbury addresses a range of therapeutic areas, providing solutions for common and complex health challenges. With a dedication to quality and patient well-being, the company strives to deliver effective and accessible medicines that enhance the lives of people worldwide. Wanbury's integrated approach encompasses research and development, manufacturing excellence, and strategic partnerships, all of which contribute to its sustained growth and success in the competitive pharmaceutical landscape. Wanbury's formulation offerings cover a wide range of medical needs, from managing common ailments to addressing more specialized conditions. Its anti-infective range battles bacterial and viral infections, while its pain and analgesics provide relief for various types of discomfort. Wanbury's product lineup also includes formulations for respiratory conditions, gastroenterological disorders, gynecological health, rheumatological issues, and central nervous system disorders. The company understands the importance of overall health and well-being, and it also provides a comprehensive range of vitamins, minerals, and nutritional supplements. By addressing diverse therapeutic needs, Wanbury plays a vital role in promoting health and improving the quality of life for patients across different demographics. Wanbury's API division plays a crucial role in the pharmaceutical supply chain, providing essential ingredients for a variety of medications. The company manufactures APIs for antidiabetics, helping to manage blood sugar levels in diabetic patients. It also produces APIs for antihistamines, offering relief from allergy symptoms, and for antitussives, which alleviate coughs. Wanbury's API portfolio extends to analgesics, antidepressants, and anti-inflammatory medicines, supporting the production of drugs that address pain, mood disorders, and inflammation. Through its commitment to quality and reliability, Wanbury contributes to the availability of effective and affordable medications, empowering healthcare professionals and patients alike.
Company Details
Key Leadership
WANBURY Share Price: Frequently Asked Questions
What is the current share price of Wanbury Limited?
Wanbury Limited (WANBURY) trades at ₹222.60 on NSE and BSE. Market cap ₹777.75 (Cr). Educational data only.
What is the P/E ratio of Wanbury Limited?
Wanbury Limited has a P/E of 12.82x vs industry average 34.89x.
What is the Bull Run score for Wanbury Limited?
Wanbury Limited has a Bull Run score of 33.8/100 based on 25+ financial parameters.
Does Wanbury Limited pay dividends?
Wanbury Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Wanbury Limited?
Wanbury Limited has ROE of 64.93%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Wanbury Limited?
Wanbury Limited has debt-to-equity of 1.49.
Is Wanbury Limited a good investment?
Bull Run gives Wanbury Limited a score of 33.8/100. This is not investment advice — consult a SEBI-registered advisor.